Ni Wang

Ni Wang

Auto-generated profile, based on publicly available information

Ni Wang

Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Key Laboratory of Medical Neurobiology of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
YDYi Dong
Yi Dong
Rou-Min WangRou-Min Wang
Rou-Min Wang
Guo-Min YangGuo-Min Yang
Guo-Min Yang
HYHao Yu
Hao Yu
WXWan-Qing Xu
Wan-Qing Xu
Zhi-Ying WuZhi-Ying Wu
Zhi-Ying Wu

2 April 2022 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Open access
AEAnders U. Eliasen
Anders U. Eliasen
CPCasper Emil T. Pedersen
Casper Emil T. Pedersen
MRMorten Arendt Rasmussen
Morten Arendt Rasmussen
NWNi Wang
Ni Wang
MSMatteo Soverini
Matteo Soverini
KBKlaus Bønnelykke
Klaus Bønnelykke
Asthma with severe exacerbation is one of the most common causes of hospitalization among young children. Exacerbations are typically triggered by respiratory infections, but the host factors causing recurrent infections and exacerbations in some children are poorly understood. As a result, current treatment options and preventive measures are inadequate. We sought to identify genetic interaction associated with the development of childhood asthma. We performed an exhaustive search for pairwise interaction between genetic single nucleotide polymorphisms using 1204 cases of a specific phenotype of early childhood asthma with severe exacerbations in patients aged 2 to 6 years combined with 5328 nonasthmatic controls. Replication was attempted in 3 independent populations, and potential underlying immune mechanisms were investigated in the COPSAC2010 and COPSAC2000 birth cohorts. We found evidence of interaction, including replication in independent populations, between the known childhood asthma loci CDHR3 and GSDMB. The effect of CDHR3 was dependent on the GSDMB genotype, and this interaction was more pronounced for severe and early onset of disease. Blood immune analyses suggested a mechanism related to increased IL-17A production after viral stimulation. We found evidence of interaction between CDHR3 and GSDMB in development of early childhood asthma, possibly related to increased IL-17A response to viral infections. This study demonstrates the importance of focusing on specific disease subtypes for understanding the genetic mechanisms of asthma.

6 November 2023 in Oncogenesis
Verified
Journal Article
Open access
PDF file
GYGang Yan
Gang Yan
MDMeiou Dai
Meiou Dai
SPSophie Poulet
Sophie Poulet
NWNi Wang
Ni Wang
JBJulien Boudreault
Julien Boudreault
JLJean-Jacques LEBRUN
Jean-Jacques LEBRUN
Triple negative breast cancer (TNBC) is defined as lacking the expressions of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). TNBC patients exhibit relatively poor clinical outcomes due to lack of molecular markers for targeted therapies. As such chemotherapy often remains the only systemic treatment option for these patients. While chemotherapy can initially help shrink TNBC tumor size, patients eventually develop resistance to drug, leading to tumor recurrence. We report a combined in vitro/in vivo genome-wide CRISPR synthetic lethality screening approach in a relevant TNBC cell line model to identify several targets responsible for the chemotherapy drug, paclitaxel resistance. Computational analysis integrating in vitro and in vivo data identified a set of genes, for which specific loss-of-function deletion enhanced paclitaxel resistance in TNBC. We found that several of these genes (ATP8B3, FOXR2, FRG2, HIST1H4A) act as cancer stemness negative regulators. Finally, using in vivo orthotopic transplantation TNBC models we showed that FRG2 gene deletion reduced paclitaxel efficacy and promoted tumor metastasis, while increasing FRG2 expression by means of CRISPR activation efficiently sensitized TNBC tumors to paclitaxel treatment and inhibited their metastatic abilities. In summary, the combined in vitro/in vivo genome-wide CRISPR screening approach proved effective as a tool to identify novel regulators of paclitaxel resistance/sensitivity and highlight the FRG2 gene as a potential therapeutical target overcoming paclitaxel resistance in TNBC.

3 June 2024 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
SPSophie Poulet
Sophie Poulet
MDMeiou Dai
Meiou Dai
NWNi Wang
Ni Wang
GYGang Yan
Gang Yan
JBJulien Boudreault
Julien Boudreault
JLJean-Jacques LEBRUN
Jean-Jacques LEBRUN
Triple negative breast cancer (TNBC) remains exceptionally challenging to treat. While CDK4/6 inhibitors have revolutionized HR + breast cancer therapy, there is limited understanding of their efficacy in TNBC and meaningful predictors of response and resistance to these drugs remain scarce. We conducted an in vivo genome-wide CRISPR screen using palbociclib as a selection pressure in TNBC. Hits were prioritized using microarray data from a large panel of breast cancer cell lines to identify top palbociclib sensitizers. Our study defines TGFβ3 as an actionable determinant of palbociclib sensitivity that potentiates its anti-tumor effects. Mechanistically, we show that chronic palbociclib exposure depletes p21 levels, contributing to acquired resistance, and that TGFβ3 treatment can overcome this. This study defines TGFβ3 as an actionable biomarker that can be used to improve patient stratification for palbociclib treatment and exploits the synergistic interaction between CDK4/6 and TGFβ3 to propose a new combinatorial treatment for TNBC.

4 August 2021 in Metabolic Brain Disease
Verified
Journal Article
Closed access
PDF file
WXWan-Qing Xu
Wan-Qing Xu
WNWang Ni
Wang Ni
Rou-Min WangRou-Min Wang
Rou-Min Wang
YDYi Dong
Yi Dong
Zhi-Ying WuZhi-Ying Wu
Zhi-Ying Wu

13 September 2020 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
JXJuan‐Juan Xie
Juan‐Juan Xie
WNWang Ni
Wang Ni
QWQiao Wei
Qiao Wei
Zhi-Ying WuZhi-Ying Wu
Zhi-Ying Wu